4
|
Kelly RS, Roulland S, Morgado E, Sungalee S, Jouve N, Tumino R, Krogh V, Panico S, Polidoro S, Masala G, Sánchez MJ, Chirlaque MD, Sala N, Gurrea AB, Dorronsoro M, Travis RC, Riboli E, Gunter M, Murphy N, Vermeulen R, Bueno-de-Mesquita HB, Peeters PH, Trichopoulou A, Trichopoulos D, Lagiou P, Nieters A, Canzian F, Kaaks R, Boeing H, Weiderpass E, Stocks T, Melin B, Overvad K, Tjønneland A, Olsen A, Brennan P, Johansson M, Nadel B, Vineis P. Determinants of the t(14;18) translocation and their role in t(14;18)-positive follicular lymphoma. Cancer Causes Control 2015; 26:1845-55. [PMID: 26424368 DOI: 10.1007/s10552-015-0677-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2015] [Accepted: 09/22/2015] [Indexed: 11/29/2022]
Abstract
PURPOSE The strong association between t(14;18) translocation and follicular lymphoma (FL) is well known. However, the determinants of this chromosomal aberration and their role in t(14;18) associated FL remain to be established. METHODS t(14;18) frequency within the B cell lymphoma 2 major breakpoint region was determined for 135 incident FL cases and 251 healthy controls as part of a nested case-control study within the European Prospective Investigation into Cancer cohort. Quantitative real-time PCR was performed in DNA extracted from blood samples taken at recruitment. The relationship between prevalence and frequency of the translocation with baseline anthropometric, lifestyle, and dietary factors in cases and controls was determined. Unconditional logistic regression was used to explore whether the risk of FL associated with these factors differed in t(14;18)(+) as compared to t(14;18)(-) cases. RESULTS Among incident FL cases, educational level (χ(2) p = 0.021) and height (χ(2) p = 0.025) were positively associated with t(14;18) prevalence, and cases with high frequencies [t(14;18)(HF)] were significantly taller (t test p value = 0.006). These findings were not replicated in the control population, although there were a number of significant associations with dietary variables. Further analyses revealed that height was a significant risk factor for t(14;18)(+) FL [OR 6.31 (95% CI 2.11, 18.9) in the tallest versus the shortest quartile], but not t(14;18)(-) cases. CONCLUSIONS These findings suggest a potential role for lifestyle factors in the prevalence and frequency of the t(14;18) translocation. The observation that the etiology of FL may differ by t(14;18) status, particularly with regard to height, supports the subdivision of FL by translocation status.
Collapse
Affiliation(s)
- Rachel S Kelly
- MRC/PHE Centre for Environment and Health, School of Public Health, Imperial College London, St Mary's Campus Norfolk Place, London, W2 1PG, UK
- Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA
| | - Sandrine Roulland
- Center of Immunology of Marseille-Luminy (CIML), Université de la Méditerranée, Marseille, France
- INSERM U631, Marseille, France
- CNRS UMR6102, Marseille, France
| | - Ester Morgado
- Center of Immunology of Marseille-Luminy (CIML), Université de la Méditerranée, Marseille, France
- INSERM U631, Marseille, France
- CNRS UMR6102, Marseille, France
| | - Stéphanie Sungalee
- Center of Immunology of Marseille-Luminy (CIML), Université de la Méditerranée, Marseille, France
- INSERM U631, Marseille, France
- CNRS UMR6102, Marseille, France
| | - Nathalie Jouve
- Center of Immunology of Marseille-Luminy (CIML), Université de la Méditerranée, Marseille, France
- INSERM U631, Marseille, France
- CNRS UMR6102, Marseille, France
| | - Rosario Tumino
- Cancer Registry and Histopathology Unit, "Civic - M.P.Arezzo" Hospital, ASP Ragusa, Ragusa, Italy
| | - Vittorio Krogh
- Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - Salvatore Panico
- Department of Clinical and Experimental Medicine, Federico II University, Naples, Italy
| | | | - Giovanna Masala
- Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute - ISPO, Florence, Italy
| | - María-José Sánchez
- Escuela Andaluza de Salud Pública, Instituto de Investigación Biosanitaria de Granada (Granada.ibs), Granada, Spain
- CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
| | - Maria-Dolores Chirlaque
- CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
- Department of Epidemiology, Murcia Regional Health Authority, Murcia, Spain
| | - Núria Sala
- Unit of Nutrition and Cancer, Cancer Epidemiology Research Program and Translational Research Laboratory, Catalan Institute of Oncology (IDIBELL), Barcelona, Spain
| | - Aurelio Barricarte Gurrea
- CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
- Navarre Public Health Institute, Pamplona, Spain
| | - Miren Dorronsoro
- Public Health Direction and Ciberesp-Biodonostia Basque Regional Health Department, Vitoria, Spain
| | - Ruth C Travis
- Cancer Epidemiology Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK
| | - Elio Riboli
- MRC/PHE Centre for Environment and Health, School of Public Health, Imperial College London, St Mary's Campus Norfolk Place, London, W2 1PG, UK
| | - Marc Gunter
- MRC/PHE Centre for Environment and Health, School of Public Health, Imperial College London, St Mary's Campus Norfolk Place, London, W2 1PG, UK
| | - Neil Murphy
- MRC/PHE Centre for Environment and Health, School of Public Health, Imperial College London, St Mary's Campus Norfolk Place, London, W2 1PG, UK
| | - Roel Vermeulen
- Division of Environmental Epidemiology, Institute for Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands
| | - H B Bueno-de-Mesquita
- Department for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
- Department of Gastroenterology and Hepatology, University Medical Centre, Utrecht, The Netherlands
| | - Petra H Peeters
- Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, 3508 GA, Utrecht, The Netherlands
| | - Antonia Trichopoulou
- Hellenic Health Foundation, 13 Kaisareias Street, 115 27, Athens, Greece
- Bureau of Epidemiologic Research, Academy of Athens, 23 Alexandroupoleos Street, 115 27, Athens, Greece
| | - Dimitrios Trichopoulos
- Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA
- Hellenic Health Foundation, 13 Kaisareias Street, 115 27, Athens, Greece
- Bureau of Epidemiologic Research, Academy of Athens, 23 Alexandroupoleos Street, 115 27, Athens, Greece
| | - Pagona Lagiou
- Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA
- Bureau of Epidemiologic Research, Academy of Athens, 23 Alexandroupoleos Street, 115 27, Athens, Greece
- Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School, 75 M. Asias Street, Goudi, 115 27, Athens, Greece
| | - Alexandra Nieters
- Center for Chronic Immunodeficiency, University Medical Center Freiburg, Freiburg, Germany
| | - Federico Canzian
- Genomic Epidemiology Group, German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany
| | - Rudolf Kaaks
- Genomic Epidemiology Group, German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany
| | - Heiner Boeing
- Department of Epidemiology, German Institute of Human Nutrition (DIfE), Potsdam-Rehbrüucke, Nuthetal, Germany
| | - Elisabete Weiderpass
- Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Tromsø, Norway
- Cancer Registry of Norway, Oslo, Norway
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
- Department of Genetic Epidemiology, Folkhälsan Research Center, Helsinki, Finland
| | - Tanja Stocks
- Department of Clinical Sciences in Malmö, Lund University, Lund, Sweden
- Department of Perioperative and Surgical Sciences, Umeå University, Umeå, Sweden
| | - Beatrice Melin
- Department of Radiation Sciences, Head Regional Cancer Center North, Umeå University, Umeå, Sweden
| | - Kim Overvad
- Section for Epidemiology, Department of Public Health, Aarhus University, Aarhus, Denmark
| | | | - Anja Olsen
- Danish Cancer Society Research Center, Copenhagen, Denmark
| | - Paul Brennan
- International Agency for Research on Cancer (IARC-WHO), 69372, Lyon, France
| | - Mattias Johansson
- International Agency for Research on Cancer (IARC-WHO), 69372, Lyon, France
| | - Bertrand Nadel
- Center of Immunology of Marseille-Luminy (CIML), Université de la Méditerranée, Marseille, France
- INSERM U631, Marseille, France
- CNRS UMR6102, Marseille, France
| | - Paolo Vineis
- MRC/PHE Centre for Environment and Health, School of Public Health, Imperial College London, St Mary's Campus Norfolk Place, London, W2 1PG, UK.
- HuGeF - Human Genetics Foundation, Turin, Italy.
| |
Collapse
|
5
|
Altekruse SF, Rosenfeld GE, Carrick DM, Pressman EJ, Schully SD, Mechanic LE, Cronin KA, Hernandez BY, Lynch CF, Cozen W, Khoury MJ, Penberthy LT. SEER cancer registry biospecimen research: yesterday and tomorrow. Cancer Epidemiol Biomarkers Prev 2015; 23:2681-7. [PMID: 25472677 DOI: 10.1158/1055-9965.epi-14-0490] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
The National Cancer Institute's (NCI) Surveillance, Epidemiology, and End Results (SEER) registries have been a source of biospecimens for cancer research for decades. Recently, registry-based biospecimen studies have become more practical, with the expansion of electronic networks for pathology and medical record reporting. Formalin-fixed paraffin-embedded specimens are now used for next-generation sequencing and other molecular techniques. These developments create new opportunities for SEER biospecimen research. We evaluated 31 research articles published during 2005 to 2013 based on authors' confirmation that these studies involved linkage of SEER data to biospecimens. Rather than providing an exhaustive review of all possible articles, our intent was to indicate the breadth of research made possible by such a resource. We also summarize responses to a 2012 questionnaire that was broadly distributed to the NCI intra- and extramural biospecimen research community. This included responses from 30 investigators who had used SEER biospecimens in their research. The survey was not intended to be a systematic sample, but instead to provide anecdotal insight on strengths, limitations, and the future of SEER biospecimen research. Identified strengths of this research resource include biospecimen availability, cost, and annotation of data, including demographic information, stage, and survival. Shortcomings include limited annotation of clinical attributes such as detailed chemotherapy history and recurrence, and timeliness of turnaround following biospecimen requests. A review of selected SEER biospecimen articles, investigator feedback, and technological advances reinforced our view that SEER biospecimen resources should be developed. This would advance cancer biology, etiology, and personalized therapy research. See all the articles in this CEBP Focus section, "Biomarkers, Biospecimens, and New Technologies in Molecular Epidemiology." Cancer Epidemiol Biomarkers Prev; 23(12); 2681-7. ©2014 AACR.
Collapse
Affiliation(s)
- Sean F Altekruse
- Division of Cancer Control and Population Sciences, National Cancer Institute, NIH, Rockville, Maryland.
| | - Gabriel E Rosenfeld
- Division of Cancer Control and Population Sciences, National Cancer Institute, NIH, Rockville, Maryland
| | - Danielle M Carrick
- Division of Cancer Control and Population Sciences, National Cancer Institute, NIH, Rockville, Maryland
| | - Emilee J Pressman
- Division of Cancer Control and Population Sciences, National Cancer Institute, NIH, Rockville, Maryland
| | - Sheri D Schully
- Division of Cancer Control and Population Sciences, National Cancer Institute, NIH, Rockville, Maryland
| | - Leah E Mechanic
- Division of Cancer Control and Population Sciences, National Cancer Institute, NIH, Rockville, Maryland
| | - Kathleen A Cronin
- Division of Cancer Control and Population Sciences, National Cancer Institute, NIH, Rockville, Maryland
| | | | - Charles F Lynch
- Department of Epidemiology, College of Public Health, The University of Iowa, Iowa City, Iowa
| | - Wendy Cozen
- Department of Preventive Medicine, Keck School of Medicine of the University of Southern California (USC), USC Norris Comprehensive Cancer Center, Los Angeles, California. Department of Pathology, Keck School of Medicine of the University of Southern California (USC), USC Norris Comprehensive Cancer Center, Los Angeles, California
| | - Muin J Khoury
- Division of Cancer Control and Population Sciences, National Cancer Institute, NIH, Rockville, Maryland. Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia
| | - Lynne T Penberthy
- Division of Cancer Control and Population Sciences, National Cancer Institute, NIH, Rockville, Maryland
| |
Collapse
|
7
|
Weitmann K, Hirt C, Schwarz S, Rabkin C, Dölken G, Hoffmann W. Influence of reproductive history and exogenous hormone use on prevalence and frequency of circulating t(14;18)-positive cells in a population-based cross-sectional study. Cancer Causes Control 2015; 26:455-65. [PMID: 25634026 PMCID: PMC4331597 DOI: 10.1007/s10552-015-0525-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2014] [Accepted: 01/10/2015] [Indexed: 11/28/2022]
Abstract
Purpose The t(14;18) translocation might represent an intermediate step in the pathogenesis of follicular lymphoma (FL), one of the most common subtypes of non-Hodgkin lymphoma. Circulating t(14;18)-positive cells can also be detected in 30–60 % of healthy individuals at low frequencies. Some studies found a negative association between reproductive factors or use of menopausal hormone therapy (MHT) with FL. The objective of this study was to evaluate whether there is an association between number of frequencies, oral contraceptive (OC) use, menopausal status and MHT, and t(14;18) prevalence and frequency in a representative population analysis based on an epidemiologic study in the northeastern part of Germany. Methods The analysis is based on results of buffy coat samples from 1,981 women of the Study of Health in Pomerania (SHIP-0) and data obtained in standardized face-to-face interviews. For prevalence, odds ratios (OR) and 95 % confidence intervals (CI) were calculated using unconditional logistic regression. Frequency data were analyzed using negative binomial regression. The multivariable models included age, number of pregnancies, menopausal status (premenopausal, natural, medical/surgical menopause), OC use and MHT as a measure for exogenous hormone exposure use. Results We found no association between reproductive history and combined exogenous hormone use on the prevalence of circulating t(14;18)-positive cells. Modeling MHT and OC use separately in a sensitivity analysis, the MHT parameter yielded statistical significance [OR 1.37 (95 % CI 1.04;1.81)]. t(14;18) frequency was associated with use of OC [incidence rate ratio (IRR) for ever use 3.18 (95 % CI 1.54;6.54)], current use [IRR 3.86 (1.56;9.54)], >10 years use [IRR 3.93 (1.67;9.23)] and MHT [restricted to postmenopausal women; IRR 2.63 (95 % CI 1.01;6.85)] in bivariate age-adjusted analyses. In the multivariable model, medical/surgical menopause [IRR 2.46 (1.11;5.44)] and the category ever use of OC and MHT were statistically significant [IRR 2.41 (1.09;5.33)]. Conclusions Exogenous hormone use might be a risk factor for t(14;18) frequency rather than for t(14;18) prevalence. Further research on healthy individuals carrying a t(14;18) translocation and possible risk factors for malignant lymphoma is necessary to determine the additional molecular or immunological events that have to occur to develop FL. Electronic supplementary material The online version of this article (doi:10.1007/s10552-015-0525-4) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Kerstin Weitmann
- Department Epidemiology of Health Care and Community Health, Institute for Community Medicine, University Medicine Greifswald, Ellernholzstr. 1-2, 17487, Greifswald, Germany,
| | | | | | | | | | | |
Collapse
|